Dizal’s Phase III NSCLC trial of Zegfrovy meets primary endpoint

The open-label trial enrolled patients across 16 countries and regions in Europe, Asia, South America, and North America.

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell ...
pharmaphorum

Dizal breaks new ground for EGFR drugs in lung cancer

Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 trial as a first-line treatment for non-small cell lung cancer (NSCLC) with ...

Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play

Verastem (VSTM) stock receives a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts ...
Medscape

First-Line Osimertinib Plus Chemo Extends Survival in NSCLC

The final overall survival (OS) results of the FLAURA2 trial support osimertinib plus chemotherapy as the new first-line standard of care for EGFR-mutated non-small cell lung cancer (NSCLC), according ...
Targeted Oncology

Phase 3 Trial of Eftilagimod Alfa in First-Line NSCLC Halted After Futility Analysis

TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...

TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...